Amgen Inc (BUE:AMGN)
ARS 10400 250 (2.46%) Market Cap: 151.64 Til Enterprise Value: 203.40 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 57/100

Amgen Inc at BMO Capital Markets Prescription for Success Healthcare Conference (Virtual) Transcript

Jun 23, 2020 / 08:00PM GMT
Release Date Price: ARS5200
Guyn Kim
BMO Capital Markets Equity Research - Analyst

Good afternoon. My name is Do Kim. I'm one of the biotech analysts here at BMO. For our next presentation and fireside chat, we're happy to have with us, Elliott Levy, Senior Vice President of R&D Strategy and Operations; and Arvind Sood, Head of IR at Amgen. Start maybe, Elliott, you could have some opening comments and talk to Amgen's priority for clinical development.

Elliott M. Levy
Amgen Inc. - SVP of R&D Strategy and Operations

Great. Thanks for giving me the opportunity to speak today. At Amgen, our focus is on development of first-in-class therapies in areas of high unmet medical need. We look for areas where we can bring value based on our established capabilities in protein discovery and development, in immunology, and unique platforms like our BiTE platform. And we focus on 3 therapeutic areas: hematology, oncology, inflammation and cardiovascular disease.

We have a number of key data readouts later this year. These include our potentially pivotal study with AMG 510 or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot